Treatment of Multiple Oral Ulcers
For multiple oral ulcers consistent with recurrent aphthous stomatitis, start with topical corticosteroids (triamcinolone acetonide) as first-line therapy, combined with topical antiseptics or local anesthetics for immediate pain relief 1, 2.
Treatment Algorithm by Severity
Mild Cases (Few ulcers, tolerable pain)
- Topical antiseptics and local anesthetics (lidocaine) should be tried first 2
- If ineffective after 3-5 days, escalate to topical corticosteroids
- Avoid sodium lauryl sulfate-containing toothpastes, hard/acidic/salty foods, alcohol, and carbonated drinks 2
Moderate Cases (Multiple ulcers, significant pain)
- Topical corticosteroids (triamcinolone acetonide) as primary treatment 1, 2
- Add amlexanox (topical anti-inflammatory) for enhanced healing 1
- Hyaluronic acid shows favorable efficacy with excellent safety profile 3
- Low-level laser therapy consistently reduces pain and shortens healing time 3
Severe/Refractory Cases (Compromising quality of life, frequent recurrences)
When topical measures fail:
- Systemic corticosteroids (prednisone) for acute severe episodes 1, 2
- Colchicine for maintenance therapy and recurrence prevention 4, 5
- Roflumilast (phosphodiesterase-4 inhibitor) shows 88% reduction in flare-ups and 94% reduction in ulcers, with good tolerability at low doses 6 - this represents the most recent high-quality evidence for severe RAS
- Thalidomide is most effective but reserved for truly refractory cases due to significant adverse effects 1, 4
- Apremilast as alternative immunomodulator 5
Critical Diagnostic Considerations
Before treating as simple RAS, rule out secondary causes 7, 8:
- Behçet's disease (bipolar aphthosis - oral + genital ulcers)
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Nutritional deficiencies (iron, folate, B12)
- Celiac disease
- HIV infection or neutropenia
- Malignancy - any solitary chronic ulcer requires biopsy 4
Evidence Quality Notes
The 2026 umbrella review 3 provides the highest-level synthesis, confirming topical corticosteroids and low-level laser therapy have the strongest evidence for pain reduction and healing acceleration. However, evidence for preventing recurrence remains limited across all interventions.
The 2024 roflumilast study 6 represents the newest systemic option with promising results (88% flare-up reduction), though it requires confirmation in larger controlled trials. Its advantage is the lack of need for close monitoring and favorable safety profile at low doses.
Common Pitfalls to Avoid
- Don't assume all oral ulcers are RAS - the differential is extensive 7, 8. Any ulcer persisting >3 weeks requires biopsy
- Don't use systemic immunosuppressants as first-line - reserve for refractory cases due to adverse effect profiles 2
- Don't overlook underlying systemic disease - particularly in patients with unusually severe or persistent ulcers 8, 5
- Don't continue ineffective topical therapy indefinitely - escalate to systemic treatment when multiple painful ulcerations compromise quality of life 9